The Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System is a prescription drug abuse, misuse and diversion surveillance system that collects timely product-and geographically-specific data.

 

The RADARS System measures rates of abuse, misuse and diversion throughout the United States, contributing to the understanding of trends and aiding the development of effective interventions. These data assist pharmaceutical companies in fulfillment of their regulatory obligations such as risk evaluation and mitigation strategies (REMS).

--Summary of Characteristics

 


  The RADARS System includes:

þ     Multiple programs

þ     Multiple distinct features and services

þ     Prescription drug abuse, misuse and diversion rate calculation using two denominators:

o        Rates per 100,000 persons provide a community-based perspective of prescription drug abuse, misuse and diversion

o        Rates per 1,000 Unique Recipients of Dispensed Drug (URDD) accounts for availability of the prescribed product in a given community. This perspective addresses the needs of health care professionals and regulatory agencies such as the U.S. Food and Drug Administration

þ     Three-digit ZIP code level identification of location of prescription drug abuse, misuse and diversion

þ     Monitoring of 11 drug substances which include more than 100 products or subcategories, each of which may be reported on and additional drug substances can easily be added

þ     Standardized procedures and quality assurance practices ensuring the accuracy and integrity of data collection and reporting

þ     Experienced, expert analysis and consultation  

þ     Research for the benefit of the scientific community and the general public

 

History

The RADARS System was developed in 2002 by Purdue Pharma L.P. in response to increasing concerns of anticipated rates of prescription opioid abuse in the United States. In January 2006, the RADARS System became a non-profit operation of the Rocky Mountain Poison and Drug Center, a division of Denver Health and Hospital Authority. The RADARS System continues to grow and evolve in an effort to address new concerns and challenges as they arise.  REMS, Opioid REMS, Risk Evaluation Mitigation Strategies, Interim REMS, REMS Metrics, REMS Compliance, REMS Evaluation, RADARS, Inflexxion, drug diversion, poison centers, abuse signals, pharmaceutical risk management, prescription abuse, drug abuse tracking, drug abuse surveillance, prescription addiction, opioid surveillance, Pinney Associates, prescription monitoring, prescription drug abuse surveillance, signal detection system, drug abuse surveillance



About the RADARS System


FDA Docket on Opioid REMS

On June 29 the RADARS System submitted comments to the FDA docket on Opioid REMS.  Please click on the link below to access the submission.



 

 

News 2.gif

Subscribe to receive RADARS System News, updates and annual meeting information.



Recent Publications

Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW. The ‘Black Box’ of Prescription Drug Diversion. Journal of Addictive Diseases. 28(4) : 332-347, 2009.

Inciardi JA, Surratt HL, Cicero TJ, Beard RA.  Prescription Opioid Abuse and Diversion in an Urban Community:  The Results of an Ultrarapid Assessment. Pain Medicine.  10(3):537-548, 2009

Inciardi JA, Surratt HL, Stivers Y, Cicero TJ.  FDA Approvals of Generic Drugs:  Impact on the Diversion of Opioid Analgesics With a Potential for Abuse. Journal of Opioid Management  5:2 81-87, March/April 2009.

 

 

 --View all Publications



Privacy Statement  |  Terms Of Use
(c) 2006 RMPDC